Rob Davis, Merck CEO (Jeenah Moon/Bloomberg via Getty Images)
Merck’s long-awaited obesity move is an oral GLP-1 from China
Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though it’s happening years after some of its big pharma peers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
